| 英文名称 |
中文名称 |
CAS |
|
Telazorlimab (anti-TNFRSF4)
|
|
2126777-87-3 |
|
Dysprosium(III) trifluoromethanesulfonate
|
三氟甲烷磺酸镝 |
139177-62-1 |
|
Bis(hexamethylene)triamine
|
双(六甲撑)三胺 |
143-23-7 |
|
Dehydroepiandrosterone sulfate
|
|
651-48-9 |
|
Xentuzumab (anti-IGF1)
|
|
1417158-65-6 |
|
Bimagrumab (anti-ACVR2B)
|
|
1356922-05-8 |
|
Meropenem-d6
|
美罗培南-d6 |
1133424-00-6 |
|
Imazapic
|
甲咪唑烟酸 |
104098-48-8 |
|
IDO-IN-13
|
|
2291164-02-6 |
|
Ethyl 2-oxo-4-phenylbutyrate
|
2-氧代-4-苯基丁酸乙酯 |
64920-29-2 |
|
Ranibizumab (anti-VEGFA)
|
|
347396-82-1 |
|
Nadecnemab (anti-GFRA3)
|
|
2377679-19-9 |
|
Benzyldiphenylphosphine
|
苄基二苯基膦 |
7650-91-1 |
|
Codrituzumab (anti-GPC3)
|
|
1365267-33-9 |
|
Urelumab (anti-TNFRSF9)
|
|
934823-49-1 |
|
Elotuzumab (anti-SLAMF7)
|
|
915296-00-3 |
|
Quetmolimab (anti-CX3CL1)
|
|
2084037-83-0 |
|
Bexmarilimab (anti-STAB1)
|
|
2259301-27-2 |
|
Narsoplimab (anti-MASP2)
|
|
2108782-45-0 |
|
8-Azahypoxanthine
|
8-氮杂次黄嘌呤 |
2683-90-1 |
|
Sirtratumab (anti-SLITRK6)
|
|
1824663-82-2 |
|
Rosmantuzumab (anti-RSPO3)
|
|
1684393-04-1 |
|
Bivatuzumab (anti-CD44v6)
|
|
214559-60-1 |
|
Apelin 17 TFA
|
Apelin 17 TFA,Apelin受体（APJ）激动剂 |
217082-57-0 |
|
Tamrintamab (anti-DPEP3)
|
|
2148325-59-9 |
|
Cinpanemab (anti-Alpha-synuclein)
|
|
2094516-02-4 |
|
Mogamulizumab (anti-CCR4)
|
|
1159266-37-1 |
|
Alizarin Yellow R sodium salt
|
茜素黄R钠盐 |
1718-34-9 |
|
2-(azetidin-1-yl)ethan-1-amine
|
2-(氮杂环丁烷-1-基)乙-1-胺 |
795299-77-3 |
|
Tesnatilimab (anti-NKG2D)
|
|
2242758-08-1 |
|
Lacnotuzumab (anti-M-CSF)
|
|
1831128-32-5 |
|
Tesidolumab (anti-Complement C5)
|
|
1531594-08-7 |
|
Sonepcizumab (anti-Sphingosine-1-phosphate)
|
|
1031360-18-5 |
|
Galiximab (anti-CD80)
|
|
357613-77-5 |
|
Idactamab (anti-SLC1A5)
|
|
2245205-37-0 |
|
Apamistamab (anti-PTPRC)
|
|
2097132-02-8 |
|
Ravulizumab (anti-Complement C5)
|
|
1803171-55-2 |
|
Itolizumab (anti-CD6)
|
|
1116433-11-4 |
|
Lumiliximab (anti-FceR2)
|
|
357613-86-6 |
|
Vopratelimab (anti-ICOS)
|
|
2039148-04-2 |
|
KWAR23 (anti-SIRPg)
|
|
2243227-60-1 |
|
Narnatumab (anti-RON)
|
|
1188275-92-4 |
|
Tisotumab (anti-F3)
|
|
1418628-81-5 |
|
Zagotenemab (anti-Tau)
|
|
2019133-28-7 |
|
Vandortuzumab (anti-STEAP1)
|
|
1557989-52-2 |
|
Ladiratuzumab (anti-SLC39A6)
|
|
1629760-28-6 |
|
Concizumab (anti-TFPI)
|
|
1312299-39-0 |
|
Serplulimab (anti-PDCD1)
|
|
2231029-82-4 |
|
Lexatumumab (anti-TNFRSF10B)
|
|
845816-02-6 |
|
Vunakizumab (anti-IL-17a)
|
|
1792181-33-9 |
|
Indusatumab (anti-GUCY2C)
|
|
1497400-26-6 |
|
Ulocuplumab (anti-CXCR4)
|
|
1375830-34-4 |
|
Vantictumab (anti-FZD)
|
|
1345009-45-1 |
|
Fulranumab (anti-NGF)
|
|
902141-80-4 |
|
Ianalumab (anti-TNFRSF13C)
|
|
1929549-92-7 |
|
Gevokizumab (anti-IL-1b)
|
|
1129435-60-4 |
|
Pascolizumab (anti-IL-4)
|
|
331243-22-2 |
|
Gemtuzumab (anti-CD33)
|
|
220578-59-6 |
|
Seribantumab (anti-ERBB3)
|
|
1334296-12-6 |
|
Tarextumab (anti-NOTCH3)
|
|
1359940-55-8 |
|
Zansecimab (anti-ANGPT2)
|
|
2415205-37-5 |
|
Vorsetuzumab (anti-CD70)
|
|
1165740-62-4 |
|
Lemzoparlimab (anti-CD47)
|
|
2377483-71-9 |
|
Flanvotumab (anti-TYRP1)
|
|
1188277-05-5 |
|
Guselkumab (anti-IL-23)
|
|
1350289-85-8 |
|
Ixekizumab (anti-CTLA-8)
|
|
1143503-69-8 |
|
Oxelumab (anti-TNFSF4)
|
|
1186098-83-8 |
|
Sirukumab (anti-IL-6)
|
|
1194585-53-9 |
|
Ragifilimab (anti-TNFRSF18)
|
|
2207590-51-8 |
|
Dostarlimab (anti-PD-1)
|
|
2022215-59-2 |
|
Otilimab (anti-GM-CSF)
|
|
1638332-55-4 |
|
Ocrelizumab (anti-CD20)
|
|
637334-45-3 |
|
Enoblituzumab (anti-CD276)
|
|
1353485-38-7 |
|
Labetuzumab govitecan (anti-CEACAM5)
|
|
1469876-18-3 |
|
Imaprelimab (anti-CD146)
|
|
2014343-04-3 |
|
Dinutuximab (anti-GD2)
|
|
1363687-32-4 |
|
Ontamalimab (anti-MADCAM1)
|
|
2098790-40-8 |
|
Enokizumab (anti-IL-9)
|
|
909875-08-7 |
|
Depatuxizumab mafodotin (anti-EGFR)
|
|
1585973-65-4 |
|
Belimumab (anti-TNFSF13B)
|
|
356547-88-1 |
|
Daclizumab (anti-IL2RA)
|
|
152923-56-3 |
|
Tinurilimab (anti-CEACAM6)
|
|
2226224-30-0 |
|
Rilotumumab (anti-HGF)
|
|
872514-65-3 |
|
Emibetuzumab (anti-MET)
|
|
1365287-97-3 |
|
Enfortumab (anti-NECTIN4)
|
|
1448664-46-7 |
|
Prezalumab (anti-B7-H2)
|
|
1523164-68-2 |
|
Avdoralimab (anti-C5AR1)
|
|
2226393-85-5 |
|
Girentuximab (anti-CA9)
|
|
916138-87-9 |
|
Datopotamab (anti-TROP2)
|
|
2267989-53-5 |
|
Abelacimab(anti-Factor XI)
|
|
2098724-83-3 |
|
Efalizumab (anti-ITGAL)
|
|
214745-43-4 |
|
Carotuximab (anti-CD105)
|
|
1268714-50-6 |
|
Brazikumab (anti-IL-23)
|
|
1610353-18-8 |
|
Eldelumab (anti-CXCL10)
|
|
946414-98-8 |
|
Daxdilimab (anti-ILT7)
|
|
2245966-28-1 |
|
Bermekimab (anti-IL-1a)
|
|
1401965-15-8 |
|
Ponsegromab (anti-GDF15)
|
|
2368950-15-4 |
|
Denintuzumab (anti-CD19)
|
|
1630074-14-4 |
|
Inebilizumab (anti-CD19)
|
|
1299440-37-1 |
|
Eculizumab (anti-Complement C5)
|
|
219685-50-4 |
